Additionally, in some studies of pediatric and adult pre B ALL, poor initial response to therapy and inferior survival were observed in patients with CDKN2A deletions [32, 33], but may be augmented with intensification of therapy with allogeneic HCT [34]. This evidence concerns the gene CDKN2A and acute lymphoblastic leukemia.